These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 25990506)

  • 1. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
    Li J; Zhou L; Chen X; Ba Y
    Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Wang H; Xu T; Zheng L; Li G
    Int J Gynecol Cancer; 2018 Jun; 28(5):903-914. PubMed ID: 29561301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment.
    Ding SS; Li L; Yu CX
    J BUON; 2014; 19(4):965-72. PubMed ID: 25536603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer.
    Wang TS; Lei W; Cui W; Wen P; Guo HF; Ding SG; Yang YP; Xu YQ; Lv SW; Zhu YL
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e95-8. PubMed ID: 25818743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Liu S; Kasherman L; Fazelzad R; Wang L; Bouchard-Fortier G; Lheureux S; Krzyzanowska MK
    Gynecol Oncol; 2021 May; 161(2):601-612. PubMed ID: 33546867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
    Hu W; Xu WS; Liao XF; He HJ
    Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibitors for the treatment of ovarian cancer.
    Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
    Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.
    Ye Q; Chen HL
    Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
    Santos LV; Cruz MR; Lopes Gde L; Lima JP
    Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: A meta-analysis.
    Chen X; Chen Y; Cai X; Zhang D; Fan L; Qiu H; Zhang B; Guo G
    J Cancer Res Ther; 2017; 13(5):869-877. PubMed ID: 29237919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials.
    Jiang Y; Sun X; Kong B; Jiang J
    Medicine (Baltimore); 2018 Aug; 97(34):e11920. PubMed ID: 30142803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
    Zhou M; Yu P; Qu X; Liu Y; Zhang J
    PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.
    Li X; Zhu S; Hong C; Cai H
    Curr Med Res Opin; 2016; 32(3):555-62. PubMed ID: 26652645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
    Guo C; Yan C; Qu L; Du R; Lin J
    Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.